Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
share Share
Annovis Bio, Inc., a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.  Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative medicine company.  The company has also announced that Jeff McGroarty has stepped away from his role as Chief Financial Officer to pursue other interests.  Mr. McGroarty will assist in an orderly transition of his duties over the next several weeks.

"The company has made substantial progress and is now reaching an exciting inflection point given the advancement of buntanetap into Phase 3 clinical trials," said Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis.  "Looking at the future of Annovis, Henry is an excellent addition to our team and will help take the company to the next level given his extensive experience in finance, accounting and strategic execution. I look forward to working closely with him to advance our mission of revolutionizing the treatment of neurodegenerative diseases."


"This is an exciting moment to be joining Annovis as it continues its mission to improve the lives of those suffering from neurodegenerative disorders," said Mr. Hagopian.  "I'm excited to join this dynamic and talented team and look forward to working with the management to advance the pipeline and contribute to its success.  I share the management team's passion to advance buntanetap, having experienced the devastating effects of neurodegenerative disease among my own close friends and family." 


Mr. Hagopian joins Annovis from Organogenesis, a Nasdaq-listed leading regenerative medicine company, where he spent 15 years of increasing responsibility, most recently as Senior Vice President, Finance and Treasurer.  In 2020, he was the company's interim Chief Financial Officer. Mr. Hagopian has an extensive background in corporate accounting, financial reporting, treasury operations, financial planning & analysis (FP&A), and investor relations.


Mr. Hagopian received both an MBA and an MS in Accounting from the Carroll Graduate School of Management at Boston College and a BS in Economics and Finance, Summa cum laude, from the Silberman College of Business at Farleigh Dickinson University.


Source: Annovis Bio, Inc.

«« World Patient Safety Day 2022: Learning about Medication Errors


Improving Antimicrobial Stewardship Programmes »»

Published on : Mon, 29 Aug 2022



Related Articles

  Vial  introduces a new member joining their  Oncology CRO  Advisory Board. Eric Jonasch, MD, is a Genitourinary Medical Oncology... Read more

New leaders will focus on making clinical trials more efficient and accessible Florence Healthcare ™ announced... Read more

Cambrian BioPharma , a multi-asset longevity biotech announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice... Read more

Annovis Bio, Inc., a clinical-stage drug platform company,neurodegenerative diseases, ,Henry Hagopian III,Chief Financial Officer Annovis Bio, Inc., a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.

No comment


Please login to leave a comment...

Highlighted Products